Arrowhead Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year	2023	2022	2021	2020	2019	2018 - 2003
Net Income	-205.28	-176.06	-140.85	-84.55	67.98	Upgrade
Depreciation & Amortization	12.49	10.42	8.27	5.94	4.44	Upgrade
Share-Based Compensation	78.13	120.89	76.67	43.38	12.39	Upgrade
Other Operating Activities	-39.24	-91.38	227.22	-60.57	88.23	Upgrade
Operating Cash Flow	-153.89	-136.13	171.31	-95.8	173.04	Upgrade
Capital Expenditures	-176.74	-52.78	-23.57	-11.95	-12	Upgrade
Change in Investments	80.58	47.36	-118.11	-228.83	-35.75	Upgrade
Investing Cash Flow	-96.16	-5.42	-141.68	-240.78	-47.75	Upgrade
Share Issuance / Repurchase	3.05	5.19	11.31	257.95	68.8	Upgrade
Debt Issued / Paid	250	0	0	0	-2.42	Upgrade
Other Financing Activities	-	60	-	-	-	Upgrade
Financing Cash Flow	253.05	65.19	11.31	257.95	66.38	Upgrade
Exchange Rate Effect	-0.12	-0.07	-0.09	0.41	0	Upgrade
Net Cash Flow	3.01	-76.36	40.94	-78.63	191.67	Upgrade
Free Cash Flow	-330.63	-188.91	147.75	-107.75	161.03	Upgrade
Free Cash Flow Margin	-137.34%	-77.67%	106.84%	-122.46%	95.40%	Upgrade
Free Cash Flow Per Share	-3.10	-1.79	1.42	-1.07	1.72	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).